Bausch Health Companies Inc.
BHC
Updated: 24/09/2026, 11:31:42
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
No summaries found.
- Share price
- $5.71
- Market cap
- $2.14B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Thomas J. Appio
- Employees
- 20,300
- IPO date
- 29/03/1994
- Beta
- 0.369
- Last dividend
- $0.00
- Day range
- $5.67 – $5.93
- 52-week range
- $4.33 – $8.00
- 1-day performance
- -1.72%
- 1-year performance
- 31.87%
- Current drawdown (1Y)
- -28.63%
- CIK
- 0000885590
- CUSIP
- 071734107
- ISIN
- CA0717341071
- Created
- 07/12/2025, 02:59:16
- Last update
- 24/09/2026, 11:31:42
Track Bausch Health Companies Inc. with an AI analyst
See which prediction-market events move BHC, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Bausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in China
PRNewsWire • STOCK • 28/05/2026, 18:15:00
Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 20/05/2026, 18:20:57
Bausch Health Announces 2026 Annual Meeting of Shareholder Results
PRNewsWire • STOCK • 19/05/2026, 18:15:00
Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript
Seeking Alpha • STOCK • 19/05/2026, 17:31:09
Why Bausch Health Companies Was Crawling Higher This Week
The Motley Fool • STOCK • 01/05/2026, 03:09:29
Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 30/04/2026, 01:01:35
Bausch Health (BHC) Lags Q1 Earnings Estimates
Zacks Investment Research • STOCK • 29/04/2026, 23:21:09
Compared to Estimates, Bausch (BHC) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research • STOCK • 29/04/2026, 23:01:21
Bausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Ordering
PRNewsWire • STOCK • 14/04/2026, 10:00:00
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026
PRNewsWire • STOCK • 31/03/2026, 09:00:00
Is the Options Market Predicting a Spike in Bausch Health Stock?
Zacks Investment Research • STOCK • 24/03/2026, 18:36:06
Bausch (BHC) Down 15.2% Since Last Earnings Report: Can It Rebound?
Zacks Investment Research • STOCK • 20/03/2026, 13:31:56